Morgan Stanley
OMGA

Morgan Stanley’s Omega Therapeutics, Inc. Common Stock OMGA Stock Holding History

Morgan Stanley’s Portfolio OMGA Stock Details OMGA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-28,572
Closed -$21.3K – 8294
2024
Q4 		$21.3K Sell
28,572
-15,411
-35% -$15.4K ﹤0.01% 6554
2024
Q3 		$53.7K Sell
43,983
-50,016
-53% -$79.6K ﹤0.01% 6197
2024
Q2 		$195K Sell
93,999
-34,564
-27% -$81.5K ﹤0.01% 5689
2024
Q1 		$469K Sell
128,563
-53,171
-29% -$204K ﹤0.01% 5345
2023
Q4 		$547K Buy
181,734
+98,432
+118% +$200K ﹤0.01% 5582
2023
Q3 		$179K Buy
83,302
+5,427
+7% +$21.7K ﹤0.01% 5634
2023
Q2 		$436K Buy
77,875
+5,746
+8% +$45K ﹤0.01% 5287
2023
Q1 		$435K Buy
72,129
+41,069
+132% +$286K ﹤0.01% 5333
2022
Q4 		$177K Buy
31,060
+13,118
+73% +$73.6K ﹤0.01% 5717
2022
Q3 		$98K Sell
17,942
-13,897
-44% -$70.4K ﹤0.01% 6085
2022
Q2 		$121K Buy
31,839
+14,847
+87% +$55.3K ﹤0.01% 6179
2022
Q1 		$106K Buy
16,992
+7,202
+74% +$73.5K ﹤0.01% 6268
2021
Q4 		$111K Buy
9,790
+9,394
+2,372% +$179K ﹤0.01% 6378
2021
Q3 		$7K Buy
+396
New +$7.6K ﹤0.01% 7424

Other funds holding OMGA

Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
PS
Principal Securities Des Moines, Iowa $6.82B AUM 17.15% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

Morgan Stanley's OMGA Position: Q1 2025 in Review

Morgan Stanley sold out of Omega Therapeutics, Inc. Common Stock (OMGA) in Q1 2025, closing a stake of 28,572 shares — an estimated $21.3K sold.

Morgan Stanley first reported a position in OMGA in Q3 2021 and held it in 14 quarters. The position peaked at $547K in Q4 2023. 4 funds tracked by Wall St. Rank hold OMGA as of Q1 2025.

  • Morgan Stanley reported no remaining Omega Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • Morgan Stanley sold 28,572 Omega Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $21.3K.
  • Morgan Stanley first reported a position in Omega Therapeutics, Inc. Common Stock in Q3 2021 and held it in 14 quarters.
  • Morgan Stanley's Omega Therapeutics, Inc. Common Stock position peaked at $547K in Q4 2023.
  • 4 funds tracked by Wall St. Rank held Omega Therapeutics, Inc. Common Stock as of Q1 2025.

Based on Morgan Stanley's 13F filing for Q1 2025, filed 15 May 2025.